Fundz

Porton Advanced Solutions Completes A Series B Financing Round To Expand Its End-To-End Gene And Cell Therapy Cdmo Platforms

PRIVATEAug 22, 2022

Round Type

Series B

SuzhouBiotechnologyTherapeutics

Description

On August 19, 2022, Porton Advanced Solutions (Porton Advanced) announced the completion of its Series B financing round with over US$80Million. Current round of financing was led by China Merchants Groups' healthcare PE fund Merchant Health, along with its sister fund China Merchants Capital, China Merchants Securities Investments. In addition, a number of renowned venture and private equity firms participated in the current round of financing, including Fosun Health Capital, Gortune Investment and SDICTK. Apart from the new investors, current Porton Advanced shareholders, Porton Pharma Solutions, CS Capital, HM Capital, Ruilian Investment and Momentum Venture, also participated in the current round

Quick answer

Porton Advanced Solutions raised an undisclosed amount in a Series B round, dated August 22, 2022. Porton Advanced Solutions is based in Suzhou, Jiangsu, China.

How much did Porton Advanced Solutions raise?
Porton Advanced Solutions raised an undisclosed amount in a Series B round on August 22, 2022.
What does Porton Advanced Solutions do?
Established in Suzhou Industrial Park in December 2018, by its parent company Porton Pharma Solutions Ltd. (Stock Code: 300363), Porton Advanced has built a CDMO platform integrating plasmid, cell therapy, gene therapy,..
Where is Porton Advanced Solutions based and how big is it?
Porton Advanced Solutions is based in Suzhou, Jiangsu, China.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Porton Advanced Solutions that raised within 45 days of this round, from Fundz verified event records.

  • Valitor raised an undisclosed amount (Series B) on October 5, 2022.
  • Vergent Bioscience raised $22M (Series B) on October 4, 2022.
  • Cellarity raised $121M (Series C) on October 4, 2022.
  • Pharnext raised an undisclosed amount (Debt Financing) on October 3, 2022.
  • iXCells Biotechnologies raised an undisclosed amount on September 29, 2022.
  • NeuShen Therapeutics raised an undisclosed amount (Funding Round) on September 29, 2022.

Who to call at Porton Advanced Solutions, and when

A new round usually means Porton Advanced Solutions is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Porton Advanced Solutions raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Porton Advanced Solutions, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Porton Advanced Solutions. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Porton Advanced Solutions

Location

Xinping Street Suzhou Industrial Park

Suzhou, Jiangsu, China

About

Established in Suzhou Industrial Park in December 2018, by its parent company Porton Pharma Solutions Ltd. (Stock Code: 300363), Porton Advanced has built a CDMO platform integrating plasmid, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy (MVGTs), providing end-to-end services from cell banking, process development and analytical development, cGMP production to final Fill and Finish , investigator-initiated clinical trials (IIT), investigational new drugs (IND), clinical trials to commercial production. Porton Advanced is dedicated to support sponsors advance their GCT drug development and market launches. Porton Advanced focuses solely on gene and cell therapy services. Built on the professional experience of its cohort of world-class professionals, as well as on the successes of its parent company, Porton Advanced insists on "Customer First" and the tenet of "Compliance, Expertise, Focus, Open Collaboration". With its key focus on protecting IP for its sponsors, through its comprehensive project management and quality systems, Porton Advanced strives to bring gene and cell therapy products to the clinic and the market through its quality CDMO services, and help bring the best medicine to the public sooner.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Porton Advanced Solutions raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Porton Advanced Solutions's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Porton Advanced Solutions raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.